Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T16:15:51.911Z.
Calculation as of: 2026-10-06T16:15:51.911Z.
Quote observation: 2026-10-06T16:15:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 29544bddba9647c45f1d116a926e76fce0232fba061b4e126f75ac7ab8440d73
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$840.81M
Free Cash Flow Yield
N/A
TTM Avg
2.73%
3Y Avg
5.44%
5Y Avg
9.24%
Market Cap
$859.14M
Free Cash Flow Yield
N/A
TTM Avg
10.05%
3Y Avg
10.05%
5Y Avg
10.05%
Market Cap
$824.96M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$825.95M
Free Cash Flow Yield
N/A
TTM Avg
1.33%
3Y Avg
1.33%
5Y Avg
1.33%
Market Cap
$876.35M
Free Cash Flow Yield
9.06%
TTM Avg
10.90%
3Y Avg
9.26%
5Y Avg
7.66%
Market Cap
$812.21M
Free Cash Flow Yield
N/A
TTM Avg
24.40%
3Y Avg
22.30%
5Y Avg
22.30%
Market Cap
$805.46M
Free Cash Flow Yield
10.86%
TTM Avg
10.11%
3Y Avg
10.17%
5Y Avg
7.95%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $844.23M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $847.45M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $840.81M | N/A | 2.73% | 5.44% | 9.24% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $859.14M | N/A | 10.05% | 10.05% | 10.05% |
| Jade Biosciences, Inc. (JBIO)vs › | $824.96M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $825.95M | N/A | 1.33% | 1.33% | 1.33% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $876.35M | 9.06% | 10.90% | 9.26% | 7.66% |
| Ardelyx, Inc. (ARDX)vs › | $812.21M | N/A | 24.40% | 22.30% | 22.30% |
| InMode Ltd. (INMD)vs › | $805.46M | 10.86% | 10.11% | 10.17% | 7.95% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $883.79M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
